TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Pomerantz Llp
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT

Pomerantz LLP is investigating potential securities fraud claims against ADC Therapeutics following the December 3, 2025 announcement of LOTIS-7 trial data. Despite positive framing, the data revealed adverse events in two patients and cytokine release syndrome in 36.7% of patients, triggering a 14.13% stock price decline to $3.95 per share.

Insights
NVO   neutral

Similar to Eli Lilly, mentioned as a medication provider without direct contractual relationship


ADCT   negative

The company faces securities fraud investigation following disclosure of significant adverse events (36.7% cytokine release syndrome rate) in clinical trial data that triggered a 14.13% stock price drop. The investigation suggests potential misrepresentation of trial safety profile to investors.